Vis enkel innførsel

dc.contributor.authorGallo, Giovanna
dc.contributor.authorMastromarino, Vittoria
dc.contributor.authorLimongelli, Giuseppe
dc.contributor.authorCalcagni, Giulio
dc.contributor.authorMaruotti, Antonello
dc.contributor.authorRagni, Luca
dc.contributor.authorValente, Fabio
dc.contributor.authorMusumeci, Beatrice
dc.contributor.authorAdorisio, Rachele
dc.contributor.authorRubino, Marta
dc.contributor.authorAutore, Camillo
dc.contributor.authorMagrì, Damiano
dc.date.accessioned2022-04-25T09:20:11Z
dc.date.available2022-04-25T09:20:11Z
dc.date.created2022-01-19T11:13:44Z
dc.date.issued2021
dc.identifier.issn2218-273X
dc.identifier.urihttps://hdl.handle.net/11250/2992450
dc.description.abstractThe usefulness of cardiopulmonary exercise test (CPET) in adult hypertrophic cardiomyopathy (HCM) patients is well-known, whereas its role in pediatric HCM patients has not yet been explored. The present study investigates possible insights from a CPET assessment in a cohort of pediatric HCM outpatients in terms of functional and prognostic assessment. Sixty consecutive pediatric HCM outpatients aged <18 years old were enrolled, each of them undergoing a full clinical assessment including a CPET; a group of 60 healthy subjects served as controls. A unique composite end-point of heart failure (HF) related and sudden cardiac death (SCD) or SCD-equivalent events was also explored. During a median follow-up of 53 months (25th–75th: 13–84 months), a total of 13 HF- and 7 SCD-related first events were collected. Compared to controls, HCM patients showed an impaired functional capacity with most of them showing peak oxygen uptake (pVO2) values of <80% of the predicted, clearly discrepant with functional New York Heart Association class assessment. The composite end-point occurred more frequently in patients with the worst CPETs’ profiles. At the univariate analysis, pVO2% was the variable with the strongest association with adverse events at follow-up (C-index = 0.72, p = 0.025) and a cut-off value equal to 60% was the most accurate in identifying those patients at the highest risk. In a pediatric HCM subset, the CPET assessment allows a true functional capacity estimation and it might be helpful in identifying early those patients at high risk of events.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleInsights from cardiopulmonary exercise testing in pediatric patients with hypertrophic cardiomyopathyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 by the authorsen_US
dc.source.articlenumber376en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3390/biom11030376
dc.identifier.cristin1984487
dc.source.journalBiomoleculesen_US
dc.identifier.citationBiomolecules. 2021, 11 (3), 376.en_US
dc.source.volume11en_US
dc.source.issue3en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal